Researcher
Hans Prenen
- Keywords (University of Antwerp):Medicine
- Disciplines (University of Antwerp):Cancer biology, Cancer diagnosis, Cancer epidemiology, Cancer prevention, Cancer therapy
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Hans Prenen (University of Antwerp)
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Oct 2020 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From12 Jul 2017 → 30 Apr 2018 - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 23 Jul 2017 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 2009 → 31 Dec 2011
Projects
1 - 7 of 7
- Exploring strategies to reduce toxicity in the multimodal treatment of esophageal cancerFrom1 Jun 2017 → 31 May 2021Funding: Nonprofit institution or equivalents
- Impact of multimodality therapy in esophageal cancer on disease, patient and treatmentFrom1 Sep 2016 → 23 May 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Unraveling the role of the PP2A regulatory subunit B55alpha in tumor-infiltrating immune cellsFrom1 Jul 2016 → 11 Feb 2022Funding: FWO Strategic Basic Research Grant, Nonprofit institution or equivalents
- Assessing the influence of weight and nutrition on recovery and quality of life after esophagectomy for cancerFrom1 Sep 2014 → 1 Jun 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of candidate biomarkers of intrinsic and acquired resistance to anti-angiogenic agents in metastatic colorectal cancer.From1 Jan 2013 → 31 Dec 2014Funding: Private funding of national origin - undefined
- The development of a proteomics procedure for the analysis of formalin-fixed paraffin-embedded tissue with the purpose of use in clinical studies.From1 Oct 2012 → 31 Dec 2017Funding: IWT personal funding - strategic basic research grants, BOF - Doctoral projects
- The search for cancer-related biomarkers: a technological challengeFrom1 Oct 2009 → 30 Jun 2014Funding: VITO (Flemish Institute for Technological Research), Private funding of national origin - undefined
Publications
1 - 10 of 91
- Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)(2021)
Authors: Eric Van Cutsem, Hans Prenen
- A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study(2019)
Authors: Hans Prenen
Pages: 121 - 130 - Impact of multimodality therapy in esophageal cancer on disease, patient and treatment(2019)
Authors: Lieven Depypere, Philippe Nafteux, Toni Lerut, Hans Prenen
- RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review(2019)
Authors: Peter A van Dam, Yannick Verhoeven, Julie Jacobs, An Wouters, Wiebren Tjalma, Filip Lardon, Tim Van den Wyngaert, Jonatan Dewulf, Evelien Smits, Cecile Colpaert, et al.
- Tumor-associated macrophages: a short compendium(2019)
Authors: Hans Prenen, Max Mazzone
Pages: 1447 - 1458 - Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases(2019)
Authors: Elleke Dresen, Frederik De Keyzer, Eric Van Cutsem, Hans Prenen, Gert De Hertogh, Albert Wolthuis, Vincent Vandecaveye
- RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment(2019)
Authors: Peter A van Dam, Yannick Verhoeven, Xuan B Trinh, An Wouters, Filip Lardon, Hans Prenen, Evelien Smits, Marcella Baldewijns, Martin Lammens
Pages: 85 - 91 - Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy(2018)
Authors: Bram Boeckx, Hans Prenen, Max Mazzone, Diether Lambrechts
- Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Kohne Prognostic Category and BRAF Mutation Status(2018)
Authors: Hans Prenen
Pages: 50 - + - Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS)(2018)
Authors: Cindy Kenis, Hans Prenen, Eric Van Cutsem, Hans Wildiers
Pages: 93 - 101